Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) announced that its subsidiaries, Tianjin Peace Pharmaceutical Co., Ltd. and Hubei Tian Pharmaceutical Co., Ltd., participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1 - The subsidiaries involved in the procurement are Tianjin Peace Pharmaceutical and Hubei Tian Pharmaceutical [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1]

Core Viewpoint - The company announced that its subsidiaries participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1: Procurement Participation - The subsidiaries of the company, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd. and Hubei Tianjin Pharmaceutical Co., Ltd., are involved in the national centralized drug procurement [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1] Group 2: Financial Impact - The total projected sales revenue from the selected products for the year 2024 is approximately 95.16 million yuan, accounting for 2.96% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue from these products is approximately 22.08 million yuan, representing 0.99% of the company's revenue for that period [1]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (600420.SH), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplemental application of Famotidine injection, which has passed the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The approval allows Famotidine injection to be used for treating upper gastrointestinal bleeding caused by various reasons, excluding tumors and esophageal or gastric variceal bleeding [1]. - Famotidine is classified as a histamine H2 receptor antagonist and is primarily used for conditions related to mucosal erosion in the stomach and duodenum [1].

Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Guoyao Group Rongsheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Famotidine injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - Guoyao Modern's subsidiary has been granted a supplementary application approval for Famotidine injection [1] - Famotidine is an H2 receptor antagonist used for treating upper gastrointestinal bleeding caused by various factors, excluding tumors and esophageal or gastric varices [1] - The approval indicates the company's capability to produce a drug that meets regulatory standards for quality and efficacy [1]

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the approval of Famotidine injection by the National Medical Products Administration highlights a significant development in the company's product portfolio and its potential impact on the market for gastrointestinal medications [1]. Company Summary - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received the approval for Famotidine injection, which has passed the consistency evaluation of generic drug quality and efficacy [1]. - Famotidine is classified as a histamine H2 receptor antagonist, primarily used for treating upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor-related conditions leading to gastric and duodenal mucosal erosion and bleeding [1].

Core Viewpoint - China National Pharmaceutical Group Modern (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of Famotidine injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval allows Famotidine injection to be used for treating upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor related conditions [1] - Famotidine is classified as a histamine H2 receptor antagonist [1] - The drug is indicated for various causes of gastric and duodenal mucosal erosion bleeding, excluding those related to tumors and esophageal or gastric varices [1]

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the approval of Famotidine injection by the National Medical Products Administration signifies a significant advancement in the company's product portfolio and its ability to meet market demands for gastrointestinal treatments [1] Group 1 - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received the approval notice for the supplementary application of Famotidine injection [1] - Famotidine is classified as a histamine H2 receptor antagonist, primarily used for treating upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor-related conditions [1] - The approval indicates that Famotidine injection has passed the consistency evaluation of generic drug quality and efficacy, enhancing its market competitiveness [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Famotidine Injection, indicating a significant advancement in the company's product pipeline and potential market expansion [1] Group 1: Product Approval - The approved drug, Famotidine Injection, is a chemical medication developed independently by the group [1] - The indication for the drug is for the treatment of upper gastrointestinal bleeding caused by peptic ulcers, excluding those due to tumors and esophageal or gastric varices [1] Group 2: Research and Development Investment - As of August 2025, the group has invested approximately RMB 7.67 million (unaudited) in the research and development of this drug [1]

Core Points - Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of Famotidine injection [1] Group 1 - The approval of Famotidine injection marks a significant milestone for the company in expanding its pharmaceutical product offerings [1]

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]